introcular pressure

Piper Jaffray said it values Glaukos Corp (NYSE: GKOS)'s suprachoroidal stent in development at $175 million based on Alcon's announcement that it paid $352 million for Glaukos competitor, Transcend, which also has a similar product. Analyst Matt O'Brien said Transcend's CyPass...